journal
MENU ▼
Read by QxMD icon Read
search

Cancer Biotherapy & Radiopharmaceuticals

journal
https://www.readbyqxmd.com/read/28622037/inhibition-of-the-akt-mtor-pathway-augments-the-anticancer-effects-of-sorafenib-in-thyroid-cancer
#1
Heqing Yi, Xuemei Ye, Bin Long, Ting Ye, Lijun Zhang, Fengqin Yan, Yang Yang, Linfa Li
BACKGROUND: Sorafenib is a multikinase inhibitor that has been approved for the treatment of patients with advanced (131)iodine ((131)I) refractory differentiated thyroid cancer (DTC). However, the progression-free survival of patients with advanced (131)I refractory DTC is short, and most DTC patients eventually acquire resistance to sorafenib. Therefore, new therapeutic strategies need to be developed. MATERIALS AND METHODS: The thyroid cancer cell lines 8505C and FTC133 were treated with sorafenib in the presence or absence of BEZ235 or small interfering RNA (siRNA) directed against AKT...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28622036/molecular-targeted-drugs-and-treatment-of-colorectal-cancer-recent-progress-and-future-perspectives
#2
Fang Geng, Zheng Wang, Hang Yin, Junxian Yu, Bangwei Cao
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world. When diagnosed, ∼50%-60% of tumors have metastasized, thus resulting in a grim prognosis. Chemotherapy is regarded as standard treatment for patients with colorectal cancer, however, limitations of chemotherapy cannot be ignored, such as low selectivity, insufficient concentrations in tumor tissues, and systemic toxicity. Recently, six targeted drugs have been approved by the U.S. Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer (mCRC), including bevacizumab, aflibercept, regorafenib, cetuximab, and panitumumab...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598691/development-of-68-ga-scn-dota-capsaicin-as-an-imaging-agent-targeting-apoptosis-and-cell-cycle-arrest-in-breast-cancer
#3
Jun Young Lee, Sang-Yeun Lee, Gun Gyun Kim, Min Goo Hur, Seung Dae Yang, Jeong-Hoon Park, Sang Wook Kim
(68)Ga-labeled capsaicin using a DOTA (1,4,7,10-tetraazocyclododecane-N,N',N″,N'″-tetraacetic acid) derivative [(68)Ga-SCN-Benzyl(Bn)-DOTA-capsaicin] was studied for the diagnosis of breast cancers, such as MCF-7 and SK-BR-3. The standard compound, (69)Ga-SCN-Bn-DOTA-capsaicin, was also prepared and characterized by spectroscopic analysis. The binding affinity of (68)Ga-SCN-Bn-DOTA-capsaicin was evaluated by using breast cancer cell lines (MCF-7, SK-BR-3) and colon cancer cell (CT-26); the biodistribution was carried out by using MCF-7-bearing nude mice, after which the positron emission tomography (PET) images were obtained at different time intervals (15-120 minutes)...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598690/in-vitro-evaluation-of-188-re-hedp-a-mechanistic-view-of-bone-pain-palliations
#4
Rohit Sharma, Chandan Kumar, Madhava B Mallia, Mythili Kameswaran, Haladhar D Sarma, Sharmila Banerjee, Ashutosh Dash
Skeletal metastasis is common in advanced stages of various cancers, particularly of the prostate and breast carcinoma. (188)Re-HEDP (1-hydroxyethane 1, 1-diphosphonic acid) is a clinically established radiopharmaceutical for bone pain palliation of osseous metastasis, and it takes advantage of high bone affinity. The present work aims at elucidating the possible mechanisms of cell killing by (188)Re-HEDP in osteosarcoma cells and biodistribution studies in mice.(188)Re-HEDP complex was prepared by using lyophilized HEDP kits prepared in-house...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598685/radioembolization-for-unresectable-intrahepatic-cholangiocarcinoma-review-of-safety-response-evaluation-criteria-in-solid-tumors-1-1-imaging-response-and-survival
#5
Nathaniel C Swinburne, Derek M Biederman, Cecilia Besa, Nora E Tabori, Aaron M Fischman, Rahul S Patel, Francis Scott Nowakowski, Ganesh Gunasekaran, Myron E Schwartz, Robert A Lookstein, Edward Kim
The optimal palliative treatment for unresectable intrahepatic cholangiocarcinoma (ICC) remains controversial. While selective internal radiation therapy (SIRT) using yttrium-90 microspheres is a well-accepted treatment for hepatocellular carcinoma, data related to its use for locally advanced ICC remain relatively scarce. Twenty-nine patients (mean age 66 ± 11 years; 15 female) with unresectable biopsy-proven ICC treated with SIRT between June 2008 and April 2015 were retrospectively evaluated for post-treatment toxicity, overall survival, and imaging response using response evaluation criteria in solid tumors (RECIST) 1...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514209/cancer-biotherapy-more-than-immunotherapy
#6
Robert K Oldham
No abstract text is available yet for this article.
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514208/clinical-significance-and-tumor-suppressive-function-of-mir-516b-in-nonsmall-cell-lung-cancer
#7
Junfei Zhu, Youlin Zhang, Xi Yang, Litong Jin
BACKGROUND: MicroRNA-516b (miR-516b) has been recently reported to be downregulated in nonsmall cell lung cancer (NSCLC). However, its clinical significance and biological function in NSCLC remain to be clarified. MATERIALS AND METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-516b in 82 paired fresh primary tumor tissues and NSCLC cell lines. The association of miR-516b expression with clinicopathological factors and prognosis was statistically analyzed by SPSS 21...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514207/circadian-gene-clock-affects-drug-resistant-gene-expression-and-cell-proliferation-in-ovarian-cancer-skov3-ddp-cell-lines-through-autophagy
#8
Yang Sun, Long Jin, Yu-Xia Sui, Li-Li Han, Jia-Hua Liu
Abnormal autophagy regulation affects the chemoresistance of ovarian cancer, during which the circadian gene clock may play a major role. In this study, RNA interference plasmid pSUPER-Clock and overexpression plasmid pcDNA3.1-Clock of CLOCK were used to stably transfect the SKOV3/DDP cells by lipofection. Upon screening, the in vitro transfected cell lines with pSUPER-Clock, the autophagy level, and G0/G1 phase cells were significantly reduced, and the expression levels of Clock, LC3, P-gp, and MRP2 were inhibited...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514206/first-in-human-pet-ct-imaging-of-metastatic-neuroendocrine-neoplasms-with-cyclotron-produced-44-sc-dotatoc-a-proof-of-concept-study
#9
Aviral Singh, Nicholas P van der Meulen, Cristina Müller, Ingo Klette, Harshad R Kulkarni, Andreas Türler, Roger Schibli, Richard P Baum
(44)Sc is a promising positron emission tomography (PET) radionuclide (T1/2 = 4.04 hours, Eβ+average = 632 keV) and can be made available, using a cyclotron production route, in substantial quantities as a highly pure product. Herein, the authors report on a first-in-human PET/CT study using (44)Sc-DOTATOC prepared with cyclotron-produced (44)Sc. The production of (44)Sc was carried out through the (44)Ca(p,n)(44)Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation, (44)Sc was shipped to Zentralklinik Bad Berka, Germany, where radiolabeling was performed, yielding radiochemically pure (44)Sc-DOTATOC...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514205/apj-is-associated-with-treatment-response-in-gastric-cancer-patients-receiving-concurrent-chemoradiotherapy-and-endostar-therapy
#10
Yan-Zhang Hao, Mian-Li Li, Fang-Ling Ning, Xiu-Wen Wang
BACKGROUND: Endostar combined with concurrent chemoradiotherapy (CRT) has been used in patients with gastric cancers (GCs). However, there are no reliable markers to predict the treatment response and prognosis of these patients. Apelin and its receptor (APJ) are involved in angiogenesis in tumor tissues. We aimed to study whether Apelin and Apelin receptor (APJ) tumor expression can predict the treatment response of combination therapy of endostar and CRT. MATERIALS AND METHODS: We enrolled patients with locally advanced GC receiving CRT only and CRT+endostar combination therapy...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28475357/correction-to-cancer-biother-radiopharm-2017-32-3-101-110
#11
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28414551/long-noncoding-rna-mnx1-as1-knockdown-inhibits-cell-proliferation-and-migration-in-ovarian-cancer
#12
Yan Lv, Huan Li, Fengling Li, Peishu Liu, Xinrui Zhao
Long noncoding RNAs (lncRNAs) have recently emerged as pivotal regulators that govern fundamental biological processes and disease pathogenesis. LncRNA MNX1-AS1 has been reported to promote cell proliferation and invasion in gallbladder cancer, but its biological role and regulatory mechanism in ovarian cancer are poorly defined. In this study, it was found that higher expression of lncRNA MNX1-AS1 is closely associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in ovarian cancer patients...
April 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28414550/expression-of-long-noncoding-rna-urothelial-cancer-associated-1-promotes-cisplatin-resistance-in-cervical-cancer
#13
Bi Wang, Zhi Huang, Rui Gao, Zhu Zeng, Weiming Yang, Yuan Sun, Wei Wei, Zhongqing Wu, Lei Yu, Qinshan Li, Shuai Zhang, Fenghu Li, Guoli Liu, Bingjie Liu, Li Leng, Wei Zhan, Yanlong Yu, Guozhen Yang, Shi Zhou
Cisplatin resistance is still one of the main reasons for failure of clinical therapy for cervical cancer. But the underlying molecular mechanisms involved in cisplatin resistance of cervical cancer have still remained unclear. Recent studies reported that long noncoding RNAs (lncRNAs) are novel nonprotein-coding transcripts, which might play a key role in cancer biogenesis and prognosis. One of the lncRNAs, urothelial cancer associated 1 (UCA1), has been shown to promote different types of cancer cell proliferation, migration, and invasion...
April 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28380302/discrepancy-between-tumor-antigen-distribution-and-radiolabeled-antibody-binding-in-a-nude-mouse-xenograft-model-of-human-melanoma
#14
Yong-Il Kim, Jin Chul Paeng, Gi Jeong Cheon, Keon Wook Kang, Dong Soo Lee, June-Key Chung
OBJECTIVES: Biodistribution of antibodies is vital to successful immunoscintigraphy/immunotherapy, and it is assumed to be similar to antigen distribution. We measured and compared the binding pattern of radiolabeled antibody to tissue antigen distribution in a nude mouse xenograft model of human melanoma. METHODS: We transplanted 10(7) FEM-XII human melanoma cells into the right flank of five nude mice. For the control, we transplanted 5 × 10(6) LS174T human colon cancer cells into the left flank...
April 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28358602/in-vitro-incorporation-of-radioiodinated-eugenol-on-adenocarcinoma-cell-lines-caco2-mcf7-and-pc3
#15
Emine Dervis, Ayfer Yurt Kilcar, Emin Ilker Medine, Volkan Tekin, Buse Cetkin, Emre Uygur, Fazilet Zumrut Biber Muftuler
Recently, the synthesis of radiolabeled plant origin compounds has been increased due to their high uptake on some cancer cell lines. Eugenol (EUG), a phenolic natural compound in the essential oils of different spices such as Syzygium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf), has been exploited for various medicinal applications. EUG has antiviral, antioxidant, and anti-inflammatory functions and several anticancer properties. The objective of this article is to synthesize radioiodinated ((131)I) EUG and investigate its effect on Caco2, MCF7, and PC3 adenocarcinoma cell lines...
April 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28301262/-213-bi-labeled-prostate-specific-membrane-antigen-targeting-agents-induce-dna-double-strand-breaks-in-prostate-cancer-xenografts
#16
Julie Nonnekens, Kristell L S Chatalic, Janneke D M Molkenboer-Kuenen, Cecile E M T Beerens, Frank Bruchertseifer, Alfred Morgenstern, Joke Veldhoven-Zweistra, Margret Schottelius, Hans-Jürgen Wester, Dik C van Gent, Wytske M van Weerden, Otto C Boerman, Marion de Jong, Sandra Heskamp
BACKGROUND: Up to now, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy mainly focused on β-emitting radionuclides. Herein, two new (213)Bi-labeled agents for PSMA-targeted α therapy of prostate cancer (PCa) are reported. METHODS: The biodistribution of (213)Bi-labeled small-molecule inhibitor PSMA I&T and nanobody JVZ-008 was evaluated in mice bearing PSMA-positive LNCaP xenografts. DNA damage response was followed using LNCaP cells and LNCaP xenografts...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28301261/a-radiolabeled-fully-human-antibody-to-human-aspartyl-asparaginyl-%C3%AE-hydroxylase-is-a-promising-agent-for-imaging-and-therapy-of-metastatic-breast-cancer
#17
Ekaterina Revskaya, Zewei Jiang, Alfred Morgenstern, Frank Bruchertseifer, Muctarr Sesay, Susan Walker, Steven Fuller, Michael S Lebowitz, Claudia Gravekamp, Hossein A Ghanbari, Ekaterina Dadachova
There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28301260/cancer-targeting-potential-of-99m-tc-finasteride-in-experimental-model-of-prostate-carcinogenesis
#18
Gowsia Jan, Neelima D Passi, Devinder Kumar Dhawan, Vijayta Dani Chadha
This study aimed to radiolabel finasteride, a novel 5α-reductase inhibitor, to evaluate its cancer targeting potential in experimental model of prostate carcinogenesis. Finasteride was effectively radiolabeled with (99m)Tc and showed >90% labeling efficiency. The radiopharmaceutical was found to be stable up to 6 hours in rat serum at 37°C. The blood kinetics of the (99m)Tc-finasteride followed a biphasic release pattern, whereby fast-release phase was observed at 15 seconds and a slow-release phase was observed after 30 minutes of administration...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28301259/novel-treatment-of-melanoma-combined-parasite-derived-peptide-gk-1-and-anti-programmed-death-ligand-1-therapy
#19
Jesus Vera-Aguilera, Armando Perez-Torres, Diego Beltran, Cynthia Villanueva-Ramos, Mitchell Wachtel, Eduardo Moreno-Aguilera, Carlos Vera-Aguilera, Gary Ventolini, Raul Martínez-Zaguilán, Souad R Sennoune
Recent successes in the development of new therapies for metastatic melanoma, such as mitogen-activated protein kinase pathway inhibitors, anticytotoxic T lymphocyte-associated antigen-4, and programmed cell death protein 1/programmed cell death ligand 1 (PD-L1) pathway-blocking antibodies, as well as combination strategies, all yielded promising results, changing the continually evolving landscape of therapeutic options for patients with melanoma. One promising new treatment modality is based on the use of immunomodulatory monoclonal antibodies that enhance the function of components of the antitumor immune response such as T cells or block immunologic checkpoints that restrain effective antitumor immunity...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28186846/in-vitro-mouse-and-human-serum-stability-of-a-heterobivalent-dual-target-probe-that-has-strong-affinity-to-gastrin-releasing-peptide-and-neuropeptide-y1-receptors-on-tumor-cells
#20
Arijit Ghosh, Natarajan Raju, Michael Tweedle, Krishan Kumar
Receptor-targeting radiolabeled molecular probes with high affinity and specificity are useful in studying and monitoring biological processes and responses. Dual- or multiple-targeting probes, using radiolabeled metal chelates conjugated to peptides, have potential advantages over single-targeting probes as they can recognize multiple targets leading to better sensitivity for imaging and radiotherapy when target heterogeneity is present. Two natural hormone peptide receptors, gastrin-releasing peptide (GRP) and Y1, are specifically interesting as their expression is upregulated in most breast and prostate cancers...
February 2017: Cancer Biotherapy & Radiopharmaceuticals
journal
journal
32488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"